Loading...

AARTIDRUGS Aarti Drugs Ltd Litigation, disputes or regulatory action Announcement

rt D

RTDR

Aarti Drugs Ltd

(AARTIDRUGS)

2025 Announcement

Show Summary

Summary

Annual Report Dispatch

Annual Report Dispatch

Annual General Meeting

Investor Awareness Campaign

KYC Update Campaign

Share Transfer Update

Investor Meeting

Analyst Meeting

Q1 FY26 Earnings Call

Conference Call Recording

Q1FY26 Presentation

Q1 Results Released

Secretarial Auditor Appoint...

Volume Clarification

Earnings Conference Call

Compliance Certificate

IEPF Transfer Notice

Secretarial Compliance

Q4 FY25 Earnings

Financial Results Published

Conference Call Recording

Court Order Update

Investor Presentation

Q4 FY25 Performance

Earnings Call Scheduled

Compliance Certificate

Cautionary Letter

Investor Meetings

Meeting Cancellation

Regulatory Warning

SEBI Warning Letter

ESG Rating Update

Investor Meetings

Import Alert Lifted

CGST Regulatory Order

Bank Account Restored

Earnings Call Transcript

Equity Acquisition

Acquisition Announcement

Financial Results Publication

Credit Rating Update

Conference Call Recording

Investor Presentation

Q3 FY25 Results

Investment in Pinnacle

Bank Account Attachment

Earnings Conference Call

New Acquisition

Compliance Certificate

FDA Inspection Complete

New Subsidiary Created

Manufacturing Restoration

Meeting Cancellation

Investor Meetings

Investor Meeting

Earnings Call Transcript

Credit Rating Reaffirmed

Financial Results Publication

Conference Call Update

Investor Presentation

Financial Results Decline

Earnings Call Notice

Compliance Certificate

Regulatory Compliance

GMP Certification Received

Share Buyback Completed

Post Buyback Announcement

FDA Inspection Update

FDA Inspection Results

Directorate Changes

Shareholder Presentation

Buyback Extension

Buyback Extension

Buyback Extension

Investor Meeting

Buyback Announcement

Open Offer Update

Buyback Announcement

Buyback Announcement

Annual Meeting Notice

Investor Meeting

Share Buyback Announcement

Share Buyback Plan

Conditional Restart Directions

Earnings Call Transcript

Show Cause Notice

US FDA EIR Announcement

FDA EIR Receipt

Conference Call Recording U...

Financial Results Publication

Investor Presentation

Financial Results Press Rel...

Change in Director

Earnings Conference Call

Closure Announcement

Certificate Submission

Fire Incident Update

Compliance Report Submission

Investor Conference

Newspaper Publication

Conference Call Outcome

Financial Results

Investor Presentation

Financial Results Decline

Conference Call Rescheduling

Conference Call

FDA Inspection Results

Certificate Submission

Compliance Certificate Subm...

Certificate Submission

Committee Reconstitution

Appointment Of Independent ...

Directorate Change

Investor Conference

Gujarat Plant Revocation

Credit Rating Affirmed

Transcript Released

Conference Call Recording U...

Financial Results Publication

Investor Presentation

Financial Results

Earnings Conference Call

Compliances-Certificate Reg...

Certificate Under Regulatio...

Warning Letter Received

Investors Conference

Investor Conference

Transcript Release

Financial Results Publication

Conference Call Recording U...

Related Party Transactions ...

Investor Presentation

Financial Results

Earnings Conference Call

Certificate Submission

Shareholder Presentation

Credit Rating Reaffirmed

Advertisement Publication

Buyback Completion

Newspaper advertisement

Public Announcement

Buyback completion

Rights Offerings

Conference Call

Financial Statements

Financial Statements

FinancialStatements

Conference Call

Reply to Clarification

Certificate Submission

Compliance with SEBI (LODR)...

Management Changes

Earnings Call Transcript

Financial Results Publication

Conference Call

Results Presentation

External Links:

Data:

Aarti Drugs Ltd informed the stock exchanges about an ad-interim order from the Bombay High Court on May 6, 2025, which prevents the CG ST & C.Ex. Authority from taking coercive recovery actions regarding a disputed IGST demand of Rs. 230.70 Crores for FY 2017-18 to FY 2021-22.

AI Assistant

Aarti Drugs Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.